SYRESpyre Therapeutics, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$16.9M, 90 days to Oct 22, 2026), selling is often routine.
Large price swings, high volatility. Worst drawdown -99% · now 17% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SYRE take a bad year?
The deepest fall in SYRE's price history on file is −99%; it is 17% below its high today.
Altman Z-score · distress below 1.8 · safe above 3 · safe zone, the balance sheet is not what threatens this one
- Annualised volatility
- 68%
Annualised volatility · S&P 500 16% · about 4 times the market's own swing
- Worst drawdown on file
- −99%
Worst drawdown on file · −17% today
Details›
- Cash and short-term investments
- $1.15B
- Operating profit, trailing twelve months
- −$201M
- Annualised volatilitytwo years of daily moves
- 68%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 17%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
The balance sheet
What it owes against what it owns, and how close that comes to trouble.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.